NCT07564167 Ultrasound-Guided Dextrose Prolotherapy for Coccydynia: A Prospective Study
| NCT ID | NCT07564167 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Gaziosmanpasa Research and Education Hospital |
| Condition | Coccydynia |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-01-15 |
| Primary Completion | 2026-06-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2026-01-15 with a primary completion date of 2026-06-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Coccydynia is a musculoskeletal condition characterized by pain in the coccygeal region, particularly exacerbated by sitting, and is associated with impaired quality of life and functional limitation. Although various conservative and interventional treatment options are available, there remains a need for effective and safe alternative therapies, especially in treatment-resistant cases. Prolotherapy is a regenerative treatment modality that aims to reduce pain and improve function by stimulating tissue repair, particularly in ligamentous structures. While there is increasing evidence supporting its effectiveness in mechanical musculoskeletal pain conditions, the literature regarding its use in coccydynia is limited. The aim of this study is to evaluate the effect of dextrose prolotherapy on pain severity and functional status in patients diagnosed with coccydynia. This study is designed as a prospective, single-arm, open-label interventional study. Patients will receive 15% dextrose prolotherapy according to a standardized protocol. Pain severity will be assessed using the Visual Analog Scale (VAS), and functional status will be evaluated using the Dallas Pain Questionnaire before treatment and at 1 month after completion of the treatment. This study aims to provide more comprehensive data on the effectiveness and safety of prolotherapy in coccydynia and to contribute to the currently limited evidence in the literature.
Eligibility Criteria
Inclusion Criteria: * Age between 18 and 75 years * Pain persisting for ≥3 months and refractory to conservative treatment * Coccydynia of mechanical or idiopathic origin Exclusion Criteria: * Age \<18 years or \>75 years * Pregnancy * Allergy to the proliferant solution * Active infection * Use of anticoagulant medications * Presence of malignancy * Local abscess * Hemorrhagic diathesis * Certain types of septic arthritis * Parafunctional habits
Contact & Investigator
Merve Dikici Yagli, M.D
PRINCIPAL INVESTIGATOR
Gaziosmanpasa Research and Education Hospital
Frequently Asked Questions
Who can join the NCT07564167 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Coccydynia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07564167 currently recruiting?
Yes, NCT07564167 is actively recruiting participants. Contact the research team at mervedikici1992@gmail.com for enrollment information.
Where is the NCT07564167 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye).
Who is sponsoring the NCT07564167 clinical trial?
NCT07564167 is sponsored by Gaziosmanpasa Research and Education Hospital. The principal investigator is Merve Dikici Yagli, M.D at Gaziosmanpasa Research and Education Hospital. The trial plans to enroll 30 participants.